Key Insights on Gross Profit: AbbVie Inc. vs BioMarin Pharmaceutical Inc.

Comparing Gross Profit Trends: AbbVie vs BioMarin (2014-2023)

__timestampAbbVie Inc.BioMarin Pharmaceutical Inc.
Wednesday, January 1, 201415534000000621276000
Thursday, January 1, 201518359000000737887000
Friday, January 1, 201619805000000907234000
Sunday, January 1, 2017211760000001071860000
Monday, January 1, 2018250350000001175948000
Tuesday, January 1, 2019258270000001344582000
Wednesday, January 1, 2020304170000001336183000
Friday, January 1, 2021387510000001375760000
Saturday, January 1, 2022406400000001612370000
Sunday, January 1, 2023339030000001842161000
Monday, January 1, 2024394300000002273680000
Loading chart...

Cracking the code

A Tale of Two Pharmaceutical Giants: AbbVie Inc. vs BioMarin Pharmaceutical Inc.

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial health of key players is crucial. This analysis delves into the gross profit trends of AbbVie Inc. and BioMarin Pharmaceutical Inc. from 2014 to 2023. AbbVie, a leader in the sector, has consistently outperformed BioMarin, showcasing a staggering 170% increase in gross profit over the decade. In contrast, BioMarin's growth, while steady, reflects a more modest 196% increase.

Key Insights

  • AbbVie's Dominance: By 2022, AbbVie's gross profit peaked at approximately $40 billion, a testament to its robust product pipeline and strategic acquisitions.
  • BioMarin's Steady Climb: Despite being dwarfed by AbbVie, BioMarin's gross profit reached nearly $1.8 billion in 2023, highlighting its niche focus on rare diseases.

These insights underscore the diverse strategies and market positions of these pharmaceutical titans.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025